Founder Team

Founder and teams are with interdisplinary background of pharmacology, chemistry, physics, computer science, bioinformatics, medical science

Beijing Gigaceuticals Tech company is a novel drug development company driven by the novel artificial intelligence, owing the target independent, deep learning and gene signatures based DLEPS system. Pipelines cover aging, obesity, hyperuricemia, NASH, cancer and etc. For instance, the longevity extension compound is able to extend lifespan of mice by 145 days.

Our team

Zhengwei Xie

Founder, CEO, Experts in AI, systems biology and pharmacology.

Mingjing Gao

Experts in hyperuricemia, experienced in various animal models.

Jingxiang Wang

Pharmaceutical experts, in charge of experiments in obesity and NASH.

Zurui Liu

application programmers, model development

Cooperative Researchers

Hong Zhou

Ph.D., Assistant Professor, Peking University Health science center.

Discipline area: Cardiovascular and membrane channel pharmacology.
Research Profiles:
Majored in development of drugs for the prevention and treatment of hypertension, diabetic vascular disease, cerebral ischemia, renal ischemia reperfusion injury and polycystic kidney disease.

Xin Wang

Ph.D., associate Chief Technician, Peking University Health science center.

Research Profiles:
Majored in scientific research and teaching related to preclinical drug metabolism of new drugs/new compounds, has extension experience in drug metabolism related work, and participated in a number of research work such as the National Natural Science Foundation of China and major new drug creation projects.

Yan Liu

Peking University School of Stomatology, investigator, PHD Supervisor.

Discipline area: Biomimetic nanomaterials and dental hard tissue regeneration.
Research Profiles:
1) Biomineralization;
2) Biomimetic nanomaterials and tissue engineering;
3) Stem cells and tissue repair;
4) Tooth movement and fibril remodeling;
5) Dentin bonding

Ruimao Zheng

Peking University, researcher.

Research Profiles:
Neurometabolism (PKA participates in the neural and molecular mechanisms of metabolic diseases);
Neuroscience (Research on brain nerve pathways, molecular anatomy and dopamine receptor neurons);
Stem cell and regenerative medicine (Research on cardiovascular regenerative medicine).

Investors